LXR-Agonists Regulate ApoM Expression Differentially in Liver and Intestine

Author(s): Emine Calayir, Tatjana M. Becker, Adelheid Kratzer, Birgit Ebner, Ute Panzenbock, Jasminka Stefujl, Gerhard M. Kostner.

Journal Name: Current Pharmaceutical Biotechnology

Volume 9 , Issue 6 , 2008

Submit Manuscript
Submit Proposal


Apolipoprotein M (apoM) has been suggested to play a role in reverse cholesterol transport. Here we studied the influence of liver X-receptor (LXR) agonist on the transcriptional regulation of apoM. Studies were performed in murine liver and intestinal mucosal cells in vivo and in human intestinal Caco-2 cells in vitro. The expression of apoM was analyzed by quantitative real time PCR, and compared to well-established LXR target genes. Mice fed with TO901317 for six days showed a downregulation of apoM and apoAI in the liver to 40 % and 60 % respectively and an upregulation of Cyp7A1 to 280 %. In the small intestine, however, apoM and apoAI were upregulated by 30-60 % and ABCA1 by 250-430 %. In Caco-2 cells TO901317 caused a 60 % upregulation and the natural LXR agonist 22-hydroxycholesterol a 40 % upregulation of apoM. Possible causes for the differential effects in liver and intestine are discussed.

Keywords: Intestine, lipid metabolism, lipocalin, expression profiling

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [516 - 521]
Pages: 6
DOI: 10.2174/138920108786786376
Price: $58

Article Metrics

PDF: 5